DE-THE-LYCRA-COMPANY
1.4.2021 22:04:04 CEST | Business Wire | Press release
The LYCRA Company, a global leader in developing innovative solutions for the textile, apparel, and personal care industries, announces the appointment of Yafu Qiu, chairman of The LYCRA Company, and Julien Born, chief commercial officer of The LYCRA Company, as co-chief executive officers, effective April 1, 2021, following the retirement of David Trerotola. The co-ceo structure is intended to better implement The LYCRA Company’s new strategic development plan for the next five years and will bring greater operational focus and tap into each leader’s experience and skills in the areas most beneficial to the company to solidify its industry-leading position and drive its long-term success.
Mr. Trerotola served as the company’s chief executive officer since 2019, following the Ruyi Group’s acquisition of the business. Mr. Trerotola retires after 20 years of dedicated service to The LYCRA Company and its predecessor companies. He began his career in 1994 with DuPont.
“I want to thank Dave for his many contributions to The LYCRA Company,” said Yafu Qiu, chairman of The LYCRA Company, the company’s controlling shareholder. “Dave’s passion for the business was evident to me from the beginning, and I wish him all the best in this next phase of his journey with his wife and family. At my request, Dave will support a smooth transition of leadership and will be working with me and Julien over the next 60 days.”
Mr. Born, currently the company’s chief commercial officer, will serve as co-ceo and lead the overall operations of the company and implement its ambitious growth vision. Mr. Born joined the business in 2007 and, since 2018, led the company’s apparel business, where he managed the global commercial organization, helped strengthen R&D and innovation capabilities, and oversaw manufacturing assets. Mr. Born has also spent significant time in Asia, where he led that region over an eight-year period, with assignments in Shanghai and Hong Kong. Mr. Born has had a diverse 24-year career spent in the US, Europe and Asia, as both an executive in large multinational companies and as a business owner of a full-service corporate licensing agency. A native of Switzerland, Mr. Born holds a bachelor’s degree from Arizona State University’s W.P. Carey School of Business and a Swiss baccalaureate degree.
“The board has appointed Julien as The LYCRA Company’s next ceo,” said Mr. Qiu. “I am confident that Julien understands the opportunities and challenges facing the business and we are fully committed to supporting him and the entire leadership team on the new developments and performance growth of The LYCRA Company to help The LYCRA Company realize its full potential in 2021 and beyond.”
“I am excited for the opportunity to lead a tremendous team of colleagues at The LYCRA Company who are focused every day on creating value in the industries we serve via our unique brand portfolio, high-quality products, unparalleled innovation capabilities, and our global network of partners,” said Mr. Born. “I look forward to a close partnership with Chairman Qiu and the Ruyi Group to further develop our manufacturing capacity and accelerate the growth of our business, especially in China.”
Mr. Qiu, in addition to continuing as chairman of The LYCRA Company, will focus his co-ceo role on the company’s relationships with key stakeholders, board governance matters, strategic planning, and capital structure adjustments, including the strategy and timing of an initial public offering.
“The LYCRA Company is faced with many new challenges in a fast-developing world,” concluded Mr. Qiu. “We are taking this opportunity to appoint Mr. Born and other new management team members to work on a new strategy to further build our brand franchises, expand manufacturing capacity, develop more impactful innovations with our global value-chain partners, lead the industry in sustainability, and accelerate our digital transformation. I am confident that the new management team will be able to further strengthen the leadership role of The LYCRA Company in the apparel and personal care industries.”
About The LYCRA Company
The LYCRA Company innovates and produces fiber and technology solutions for the apparel and personal care industries. Headquartered in Wilmington, Delaware, The LYCRA Company is recognized worldwide for its innovative products, technical expertise, and unmatched marketing support. The LYCRA Company owns leading consumer and trade brands: LYCRA®, LYCRA HyFit®, LYCRA® T400®, COOLMAX®, THERMOLITE®, ELASPAN®, SUPPLEX®, and TACTEL®. The LYCRA Company’s legacy stretches back to 1958 with the invention of the original spandex yarn, LYCRA® fiber. Today, The LYCRA Company focuses on adding value to its customers’ products by developing unique innovations designed to meet the consumer’s need for comfort and lasting performance. For more information, visit www.thelycracompany.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210401005877/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
